Would you omit RNI in a patient with locally advanced TNBC with N1 disease who has an ALND and is found to have a pCR in the nodes?

This is the topic of the NRG B-51 randomized clinical trial which recently closed to new patient accrual. Until we have data from this trial, my default will be to prefer RNI in my triple negative patients known to have nodal involvement at the time of diagnosis, even if they experience a nodal pCR....

B51 would have been the answer but it finished accruing. In the meantime, I would offer RNI to TNBC no matter the response to chemo. Now that B51 closed, I would refer post mastectomy and recon patients to RTCHARM trial and for no recon or BCT, have no problem if they want to be hypofractionated (co...